TY - JOUR
T1 - Effect of bepridil in patients with chronic stable angina
T2 - Results of a multicenter trial
AU - Hill, J. A.
AU - O'Brien, J. T.
AU - Alpert, J. S.
AU - Gore, J. M.
AU - Zusman, R. M.
AU - Christensen, D.
AU - Boucher, C. A.
AU - Vetrovec, G.
AU - Borer, J. S.
AU - Friedman, C.
PY - 1985
Y1 - 1985
N2 - The effects of bepridil, a calcium antagonist with a half-life of approximately 42 hr, were assessed in a double-blind, randomized, placebo-controlled crossover trial. Forty-four patients (39 men, five women) with exercise-induced angina pectoris and ST segment depression with exercise testing (modified Bruce protocol) were studied. Compared with placebo bepridil (400 mg daily) increased total exercise time, time to onset of angina, time to 1 mm of ST segment depression, time to 2 mm of ST segment depression, and total work achieved (all p ≤ .001). Both frequency of angina and nitroglycerin consumption decreased during the bepridil compared with the placebo period (p = .02 and .03, respectively). Minor side effects were noted during both the bepridil and placebo phases. Four patients experienced side effects that limited therapy (dizziness in three and abnormal results of liver function tests in one) and one patient died during the bepridil phase. This study suggests that bepridil, 400 mg daily, is effective for the treatment of exercise-induced myocardial ischemia and angina pectoris.
AB - The effects of bepridil, a calcium antagonist with a half-life of approximately 42 hr, were assessed in a double-blind, randomized, placebo-controlled crossover trial. Forty-four patients (39 men, five women) with exercise-induced angina pectoris and ST segment depression with exercise testing (modified Bruce protocol) were studied. Compared with placebo bepridil (400 mg daily) increased total exercise time, time to onset of angina, time to 1 mm of ST segment depression, time to 2 mm of ST segment depression, and total work achieved (all p ≤ .001). Both frequency of angina and nitroglycerin consumption decreased during the bepridil compared with the placebo period (p = .02 and .03, respectively). Minor side effects were noted during both the bepridil and placebo phases. Four patients experienced side effects that limited therapy (dizziness in three and abnormal results of liver function tests in one) and one patient died during the bepridil phase. This study suggests that bepridil, 400 mg daily, is effective for the treatment of exercise-induced myocardial ischemia and angina pectoris.
UR - http://www.scopus.com/inward/record.url?scp=0022003711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022003711&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.71.1.98
DO - 10.1161/01.CIR.71.1.98
M3 - Article
C2 - 3880521
SN - 0009-7322
VL - 71
SP - 98
EP - 103
JO - Circulation
JF - Circulation
IS - 1
ER -